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ORIGINAL ARTICLE

Androgen receptor negatively regulates mitotic checkpoint
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prostate cancer
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Abstract
Background: Despite multiple treatment advances for castration‐resistant prostate

2
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cancer (CRPC), there are currently no curative therapies and patients ultimately to
succumb to the disease. Docetaxel (DTX) is the standard first‐line chemotherapy for
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patients with metastatic CRPC; however, drug resistance is inevitable and often
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develops rapidly, leading to disease progression in nearly all patients. In contrast,
when DTX is deployed with androgen deprivation therapy in castration‐sensitive
disease, more durable responses and improved outcomes are observed, suggesting
that aberrant androgen receptor (AR) signaling accelerates DTX resistance in CRPC.
In this study, we demonstrate that AR dysregulates the mitotic checkpoint, a critical
pathway involved in the anticancer action of DTX.
Methods: Androgen‐dependent and independent cell lines were used to evaluate the
role of AR in DTX resistance. Impact of drug treatment on cell viability, survival, and cell‐
cycle distribution were determined by plate‐based viability assay, clonogenic assay, and
cell‐cycle analysis by flow cytometry, respectively. Mitotic checkpoint kinase signal
transduction and apoptosis activation was evaluated by Western blotting. Pathway gene
expression analysis was evaluated by RT‐PCR. A Bliss independence model was used to
calculate synergy scores for drug combination studies.
Results: Activation of AR in hormone‐sensitive cells induces a rescue phenotype by
increasing cell viability and survival and attenuating G2/M arrest in response to DTX.
Analysis of mitotic checkpoint signaling shows that AR negatively regulates spindle
checkpoint signaling, resulting in premature mitotic progression and evasion of
apoptosis. This phenotype is characteristic of mitotic slippage and is also observed in
CRPC cell lines where we demonstrate involvement of AR splice variant AR‐v7 in
dysregulation of checkpoint signaling. Our findings suggest that DTX resistance is
mediated through mechanisms that drive premature mitotic exit. Using pharmacologic inhibitors of anaphase‐promoting complex/cyclosome and polo‐like kinase 1,
we show that blocking mitotic exit induces mitotic arrest, apoptosis, and synergistically inhibits cell survival in combination with DTX.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and is not used for commercial purposes.
© 2021 The Authors. The Prostate published by Wiley Periodicals LLC
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Conclusion: Our results suggest that targeting the mechanisms of dysregulated
mitotic checkpoint signaling in AR‐reactivated tumors has significant clinical potential to extend treatment benefit with DTX and improve outcomes in patients with
lethal prostate cancer.
KEYWORDS

cell‐cycle checkpoint, CRPC, mitotic slippage, taxane therapy
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| INTRODUCTION

Virtually all prostate cancer‐related deaths occur due to the devel-

2 |
2.1 |

METHODS
Cell lines and reagents

opment of castration resistance. Despite numerous treatment advances for castration‐resistant prostate cancer (CRPC), patients

LNCaP, VCaP, 22Rv1 (American Type Culture Collection) and LNCaP‐

relapse due to drug resistance, and ultimately succumb to the dis-

AR cells (a gift from Drs. Robert Reiter and Charles Sawyers) were

ease. Androgen receptor (AR) signaling is frequently a dominant

maintained in RPMI supplemented with 10% fetal bovine serum

driver in CRPC and remains a major therapeutic target for these

(FBS). All experiments were conducted under regular FBS conditions

patients. Second generation AR pathway inhibitors such as en-

unless specified in figure legend. In androgen deprivation conditions

zalutamide, apalutamide and abiraterone acetate demonstrate robust

(ADT), cells were grown in phenol red‐free RPMI media supple-

initial responses and increased survival benefit; however, resistance

mented with charcoal‐stripped serum for the duration of the ex-

can occur rapidly, leading to therapy failure and disease progression.

periment. Androgen (R1881) was supplemented at a concentration of

Resistance frequently occurs through alterations in AR that result in

1 nM, unless specified in the figure. Cell line authentication was

reactivation of oncogenic AR signaling (i.e., AR amplification, ligand

performed using short tandem repeat sequencing (GenePrint 10 kit;

binding domain mutations, and splice variant expression).1

Promega). All cells were routinely tested for mycoplasma using a

Docetaxel (DTX), a taxane‐based chemotherapy, is an important

mycoplasma enzyme‐based luciferase assay (MycoAlertTM PLUS

first‐line systemic therapy that extends survival for men with ad-

Mycoplasma Detection Kit; Lonza). Low passage (<15) cultures were

vanced prostate cancer.2–6 Unfortunately, up to 50% of CRPC pa-

used for all experimental testing. Enzalutamide (MDV3100), apcin,

tients do not respond to DTX, and those patients that initially

barasertib (AZD112), volasertib (BI6727), and DTX were purchased

respond will become refractory within 8 months.7 Intriguingly, when

from Selleck Chemicals. proTAME was purchased from R&D Systems.

DTX is deployed with androgen deprivation therapy (ADT) in

R1881 was purchased from Sigma‐Aldrich.

castration‐sensitive prostate cancer (CSPC), survival is improved
significantly more than for CRPC.8,9 The mechanisms that mediate
this superior response to DTX in CSPC are currently unclear. Some

2.2 |

Viability assays

studies suggest that aberrant AR alterations that are found in CRPC
may be involved in resistance to DTX.2,10

Viability was measured using the CellTiter‐GLO luminescent assay

The anticancer mechanism of action for DTX involves binding and

according to the manufacturer's instructions (Promega). Briefly, cells

disrupting microtubule dynamics, which activates the mitotic checkpoint,

were seeded into 96‐well plates 24 h before drug treatment at a

leading to protracted mitotic arrest and apoptosis. Critical to DTX's cell

density to permit exponential growth throughout the length of the

killing is inducing sustained mitotic arrest through activation of the mitotic

assay, and viability was measured 72 h after drug treatment. The

checkpoint, eventually triggering apoptosis through mitotic catastrophe.

luminescent signal was detected in 96‐well plates using a Victor X1

The mitotic checkpoint is part of the G2/M checkpoint involving multiple

Luminescence Plate Reader (Perkin Elmer). The IC50 values were

levels of regulation to ensure correct chromosome alignment and seg-

calculated using Prism v5.02 from GraphPad Software.

regation to maintain mitotic fidelity during mitosis. Importantly, defects at
several nodes of the checkpoint pathway can lead to resistance to microtubule targeting agents such as DTX, frequently through aberrant

2.3 |

Clonogenic survival

G2/M transition, weakened spindle assembly checkpoint (SAC), or
premature mitotic exit, a process known as mitotic slippage.11–13 In this

Cells were seeded into six‐well plates at a density to permit ex-

study, we sought to determine whether AR was involved in dysfunctional

ponential growth throughout the length of the assay 24 h before drug

mitotic checkpoint signaling in response to DTX and whether AR

treatment. Cells were treated every 72 h over the course of 14 days

dysregulated a specific mechanism that could be targeted to increase

after which surviving colonies were stained with 0.1% crystal violet

DTX sensitivity in CRPC.

and quantified using ImageJ software.
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to androgen withdrawal. We define in vitro ADT conditions as described in the Section 2.

Immunoblotting was conducted as previously described with

We first evaluated the impact of AR activation on DTX sensi-

minor modifications. 14 Antibodies used in the study include

tivity. Cell viability was measured in response to a dose range of DTX

cleaved PARP (#5625), cleaved Caspase‐3 (#9664), phospho‐

in cells under ADT conditions or cells in androgen‐replete conditions

AURKB (Thr232) (#2914), phospho‐Histone H3(Ser10) (#53348),

where the media is supplemented with androgen (R1881) (Figure 1A).

cyclin B (#12231) purchased from Cell Signaling Technology; AR

In both LNCaP and VCaP cells, there is more than a 2.5‐fold increase

(AR‐N20, Santa Cruz) and AR‐v7 (AG10008, Precision); glycer-

in DTX sensitivity under ADT conditions compared to conditions of

aldehyde 3‐phosphate dehydrogenase (GAPDH) (sc47724, Santa

activated AR. We observe a similar effect on clonogenic survival

Cruz) was used as protein loading control. Proteins were detected

where we demonstrate that 30% more cells survive cytotoxic levels

by infrared imaging using the Odyssey Imager and Odyssey

of DTX when supplemented with androgen (Figure 1B). The pre-

Imaging software (LI‐COR Biosciences).

dominant mechanism of cell killing by DTX is through apoptosis, and
activation of apoptosis is essential for in vitro sensitivity. We then
evaluated the effect of AR activation on apoptotic cell death in re-

2.5

| Cell‐cycle analysis

sponse to DTX by determining expression of the apoptotic markers,
cleaved caspase‐3 (cl‐Casp3) and cleaved poly (ADP‐ribose) poly-

Cells were seeded into 100 mm plates and harvested at the indicated

merase (cl‐PARP) (Figure 1C). Strikingly, the high‐level apoptotic re-

time points. Cells were washed in 1X phosphate buffered saline, fixed

sponse to DTX under ADT conditions is significantly reduced in both

with 70% ethanol and then stained with propidium iodine according to

LNCaP and VCaP cells lines when supplemented with androgen.

manufacturer's protocol (Abcam). Approximately 20,000 gated events

To evaluate the role of AR reactivation in DTX sensitivity, we

were collected, and cell‐cycle distributions were analyzed by BDFACS

employed the CRPC cell line models LNCaP‐AR and 22Rv1, re-

Diva software (BD Biosciences). Each flow cytometry analysis was per-

presenting two models of hormone‐refractory CRPC. 22Rv1 cells

formed three times.

express the AR‐v7 splice variant which confers constitutive AR activity in the absence of androgen; and LNCaP‐AR cells overexpress
AR, analogous to AR amplification.15 Evaluation of viability in re-

2.6

| Quantitative real‐time PCR

sponse to DTX showed decreased viability in all cell lines tested;
however, we observed a fivefold decrease in sensitivity in the CRPC

Total RNA (1 µg) was reverse‐transcribed using High Capacity

cell lines when comparing IC50 values (Figure 2A). Importantly, the

Complementary DNA (cDNA) Reverse Transcription Kit from Life

doses required to reach the IC50 in the CRPC cells are not clinically

Technologies. A total of 1 μl of cDNA was PCR amplified in a 20 μl

achievable.16,17 In addition, evaluation of clonogenic survival de-

reaction including TaqMan 2X Universal Master Mix and TaqMan

monstrates significantly decreased DTX response in the CRPC cell

gene expression probe/primer set for TTK, BUB1R, AURKA, AURKB,

line models (Figure 2B and Figure S1). Since we showed that AR

KIF2B, KIF2C, CDKN1A, CDKN1B, PLK1, CENPF, CDC20, CDC27,

activation blocked DTX‐induced apoptosis in CSPC cells, we asked

ANAPC5, ANAPC16, UBE2C, CCNB1, and GAPDH as an internal con-

whether this was also the case in the AR‐reactivated CRPC cells.

trol for normalized gene expression. Samples were run in triplicate for

Using a dose range of DTX, we observe that apoptosis is activated

a total of three separate experiments.

even at low doses of DTX in the CSPC cells; however, the CRPC cells
showed minimal apoptosis activation at the highest doses of DTX
(Figure 2C). Taken together, these results show that CRPC cells de-

2.7

| Statistical analysis

monstrate reduced sensitivity and diminished apoptotic response to
DTX, suggesting that oncogenic AR signaling promotes DTX

Statistical significance was assessed by the Student t test (two‐tailed

resistance.

distribution, two‐sample, unequal variance) and considered statistically significant with p value <.01.

3.2 | AR‐mediated DTX resistance is characterized
by dysregulated checkpoint signaling
3

| RESULTS
To elucidate the role of AR activation on G2/M signaling in re-

3.1 | AR activation in CSPC cells and AR
reactivation in CRPC cells induces DTX resistance

sponse to DTX, we first performed cell‐cycle analysis of DNA
content from LNCaP cells under ADT or androgen‐replete conditions. As expected, we show that DTX induces a robust G2/M

To determine the impact of AR activation on DTX response, we used

arrest in androgen‐depleted conditions (Figure 3A). Conversely,

the cell lines LNCaP and VCaP as cell line models of CSPC since both

adding androgen reduces the DTX‐induced G2/M arrest more

cell lines are dependent on androgen for growth and are responsive

than 2‐fold, suggesting that AR activation dysregulates G2/M

PILLING
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F I G U R E 1 Androgen receptor activation induces DTX resistance. (A) Viability of castration‐sensitive prostate cancer (CSPC) cell lines
LNCaP and VCaP grown in media supplemented with charcoal‐stripped serum (CSS) treated with 1 nM DTX with or without androgen
(1 nM R1881). (B) Clonogenic survival of CSPC cells treated with DTX with or without androgen. (C) Apoptosis evaluated by Western blot.
LNCaP and VCaP cells were treated with DTX with or without androgen for 18 h and lysates were probed with the indicated antibodies. *p < .01.
DTX, docetaxel [Color figure can be viewed at wileyonlinelibrary.com]

checkpoint signaling and drives mitotic entry. To characterize the

induces mitotic arrest (indicated by accumulation of cyclin B),

checkpoint response in CRPC cells, we performed cell‐cycle

consistent with the increase in G2/M population in response to

analysis in 22Rv1 and LNCaP‐AR cell lines, which revealed

DTX under ADT conditions. In contrast, when androgen is added

modest G2/M arrest in LNCaP‐AR cells and no G2/M arrest in

SAC activity is diminished, and cells escape mitotic arrest.

22Rv1 cells upon treatment with DTX (Figure 3B). We compared

To determine whether increased DTX resistance in the CRPC

the CRPC cells to LNCaP or VCaP cells under the same treatment

cells involves dysregulated SAC signaling, we evaluated SAC activa-

conditions (regular, androgen‐replete media), and observe that

tion and mitotic arrest activity in 22Rv1 and LNCaP‐AR cells com-

the CSPC cells induce G2/M arrest nearly twofold more than the

pared to the CSPC cells (Figure 3D). When treated with DTX, the

CRPC cells in response to DTX. To further analyze AR‐mediated

LNCaP‐AR and 22Rv1 cells demonstrate very low AURKB activation,

checkpoint dysregulation, we evaluated the key signaling that

while cyclin B expression is unchanged in both CRPC cell lines in

regulates mitotic arrest; the SAC. As shown in LNCaP and VCaP

response to DTX indicating failed mitotic arrest in response to DTX,

cells under ADT conditions, DTX activates the SAC; indicated by

consistent with the G2/M cell‐cycle data. In contrast, the CSPC cells,

phosphorylation of Aurora B kinase (AURKB; Thr232) and histone

treated under the same conditions as the CRPC cells, show activated

H3 (pH3; Ser10) (Figure 3C). In addition, we show that DTX

SAC and mitotic arrest.

186
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F I G U R E 2 Divergent sensitivity to docetaxel in castration‐resistant prostate cancer cells. (A) Viability in CSPC (LNCaP, VCaP) and
CRPC (LNCaP‐AR, 22Rv1) cell lines treated with DTX. The IC50 values were calculated in GraphPad. (B) Clonogenic survival of CSPC and
CRPC cells treated with DTX. (C) Apoptosis evaluated by Western blot. Cells were treated with the indicated doses of DTX for 18 h and lysates
were probed with the indicated antibodies. *p < .01 and *p < .05. CRPC, castration‐resistant prostate cancer; CSPC, castration‐sensitive
prostate cancer; DTX, docetaxel [Color figure can be viewed at wileyonlinelibrary.com]

We next tested whether AR signaling was involved in failure to

the k‐MT signaling network. KIF2B and MCAK encode two kinesin‐13

activate the checkpoint and induce mitotic arrest in the CRPC cells.

family kinases that make up the k‐MT signaling network by sensing

We treated LNCaP‐AR cells with DTX alone or with addition of the

microtubule tension and stability.21 To determine if these genes are

AR antagonist, enzalutamide (Figure 3E). Here we demonstrate sig-

responsive to AR activation, we measured mRNA transcript levels in

nificant mitotic checkpoint activation when enzalutamide is added,

LNCaP cells in response to increasing doses of androgen (Figure 4B).

and this is associated with a robust apoptosis response. Collectively,

Here we observe decreasing expression of AURKB, KIF2B, and MCAK

these results indicate that AR dysregulates mitotic checkpoint sig-

in response to increasing doses of androgen; suggesting AR nega-

naling in response to DTX and suggest that AR activation induces

tively regulates SAC signaling. This data is consistent with the signal

mitotic slippage as a mechanism of DTX resistance.

transduction data above, where AR activation attenuates DTX‐
induced SAC activation, suggesting that negative regulation of
AURKB signaling is critical for overriding the mitotic checkpoint in

3.3 | AR overrides the mitotic checkpoint through
negative regulation of AURKB signaling

response to DTX.
We next assessed whether these genes are AR‐responsive in the
CRPC cells. As shown, treatment with enzalutamide increases

To further assess the role of AR signaling in disrupting mitotic

AURKB, KIF2B, and MCAK gene expression in both LNCaP‐AR and

checkpoint signaling, we evaluated expression of genes involved in

22Rv1 cell lines; however, response is reduced compared with

critical phases of the mitotic checkpoint; G2/M transition, SAC,

LNCaP cells, likely reflecting reduced drug sensitivity in these cells

anaphase, and mitotic exit in CSPC and CRPC cell lines (Figure S2).

(Figure 4C). Since full‐length AR has been shown to mediate reg-

When we analyzed gene expression in response to enzalutamide we

ulation of mitotic checkpoint processes, both in previous studies and

found several AR‐responsive checkpoint effectors, consistent with

the data reported here, we sought to determine whether expression

18–20

Strikingly, when examining the expression of

of AR splice variants (ARVs) also influence the mitotic checkpoint.

genes in the different phases of checkpoint signaling, we observed

Importantly, ARVs have been shown to activate a distinct transcrip-

that expression of several genes involved in SAC signaling are altered

tional program enriched for mitotic regulatory genes.20 To determine

previous reports.

in response to AR inhibition (Figure 4A). Aurora B kinase (AURKB) is

whether checkpoint pathway effectors were influenced by expres-

essential for SAC activation and preventing premature anaphase.

sion of AR‐v7 expressed in 22Rv1 cells, we evaluated gene expres-

AURKB is recruited to the site of kinetochore‐microtubule (k‐MT)

sion in response to knockdown of AR‐v7. Consistent with AR‐

attachment in response to microtubule stabilization where it activates

mediated negative regulation observed in LNCaP cells, knockdown of

PILLING
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F I G U R E 3 AR‐mediated DTX resistance is characterized by attenuated mitotic arrest. (A) DNA content of LNCaP cells in CSS media treated
with 1 nM DTX with or without androgen for 18 h, stained with propidium iodide (PI) and quantified by flow cytometry. Left, representative
flow cytometry plots of DNA content. Right, bar chart of the percentage of change in the G2/M cell population after DTX treatment in cells
deprived or supplemented with androgen. (B) DNA content of the indicated cell lines treated with 1 nM DTX for 18 h, stained with PI and
quantified by flow cytometry. Left, representative flow cytometry plots of DNA content after DTX treatment for each pair of cell lines.
Right, bar chart of the percentage of change in the G2/M cell population after DTX treatment. (C) Western blot analysis for markers of mitotic
arrest in LNCaP and VCaP cells in CSS media treated with 1 nM DTX for 18 h with or without androgen. (D) Western blot analysis for
markers of mitotic arrest in the CSPC and CRPC cell lines treated with DTX for 18 h. (E) Western blot analysis for markers of mitotic arrest and
apoptosis in LNCaP‐AR cells treated with DTX alone or in combination with 20 µM enzalutamide (ENZ) for 18 h. *p < .01. AR, androgen receptor;
CRPC, castration‐resistant prostate cancer; CSPC, castration‐sensitive prostate cancer; CSS, charcoal‐stripped serum; DTX, docetaxel
[Color figure can be viewed at wileyonlinelibrary.com]

AR‐v7 (siCE3) in the 22Rv1 cells results in increased KIF2B and MCAK

resistance to DTX (Figure 4F). Investigation of checkpoint signaling

expression, while AURKB expression was unchanged in AR‐v7 si-

and apoptosis showed that DTX in combination with AURKB in-

lenced cells (Figure 4D). We next evaluated the expression of known

hibitor blocks checkpoint activation and rescues cells from apoptosis

AR‐v7 target genes that are involved in mitotic checkpoint signaling

(Figure 4G). Collectively, these findings show that AR and AR‐v7

including AURKA, UBE2C, and CDC20. As expected, expression was

negatively regulate mitotic checkpoint signaling and may promote

significantly decreased in response to AR‐v7 knockdown (Figure 4E).

premature anaphase progression, suggesting that mitotic exit can be

Intriguingly, these genes are involved in control of anaphase pro-

targeted as a potential therapeutic strategy to overcome DTX re-

gression and mitotic exit, suggesting AR‐v7 may promote premature

sistance in CRPC.

anaphase activation which has been implicated in resistance to DTX.
Since SAC inhibition leads to premature mitotic progression and
AURKB signaling is critical for sustained SAC activation, we hypothesized that AR‐mediated negative regulation of AURKB is a

3.4 | Blocking mitotic exit sensitizes CRPC cells
to DTX

potential mechanism of DTX resistance. We evaluated the effect of
blocking AURKB signaling on DTX sensitivity through pharmacologic

We demonstrate that aberrant AR activation overrides SAC signaling

inhibition of AURKB. In LNCaP cells, we measured viability in re-

in response to DTX‐induced mitotic arrest; a mechanism that has

sponse to DTX with or without addition of AURKB inhibitor bar-

been shown to limit efficacy of microtubule‐targeting agents.22

asertib (AZD1152) and show that blocking AURKB signaling induces

Premature exit from mitotic arrest occurs through activation of

188
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F I G U R E 4 AR overrides the mitotic checkpoint through negative regulation of AURKB signaling. (A) mRNA expression of the indicated genes
in LNCaP cells treated with 20 µM enzalutamide (ENZ). (B) mRNA expression in LNCaP cells in CSS media treated with the indicated doses
of androgen. (C) mRNA expression of the indicated genes in LNCaP‐AR and 22Rv1 cells treated with 20 µM ENZ. (D,E) mRNA expression in
22Rv1 cells transfected with the indicated siRNA. Right, Western blot analysis showing siRNA knockdown. (F) Viability of LNCaP cells in
CSS media treated with DTX alone, with addition of androgen, or in combination with AURKB inhibitor (AZD1152) for 72 h. (G) Western
blot analysis for markers of mitotic arrest and apoptosis in LNCaP cells in CSS media treated DTX alone, with addition of androgen,
or in combination with AURKB inhibitor (AZD1152) for 18 h. *p < .01 and *p < .05. CSS, charcoal‐stripped serum; DTX, docetaxel; mRNA,
messenger RNA; siRNA, small interfering RNA [Color figure can be viewed at wileyonlinelibrary.com]

anaphase‐promoting complex/cyclosome (APC/C), a ubiquitin ligase

CDC20 substrates, preventing substrate recognition and binding.24

that targets specific mitotic substrates, such as cyclin B and securin,

Where as proTAME disrupts the interaction between APC and

for degradation.23 We, therefore, hypothesized that blocking APC/C

CDC20 resulting in CDC20 degradation and stabilization of cy-

activity would force mitotic arrest and potentiate the apoptotic effect

clin B.25

of DTX. We tested two small molecule inhibitors of APC/C, apcin and

We first evaluated the single‐agent efficacy of these com-

proTAME, that inhibit APC/C activity through different mechanisms.

pounds in the CRPC cell lines LNCaP‐AR and 22Rv1 (Figure S3).

Apcin competitively inhibits ubiquitination of APC/C co‐activator

Apcin demonstrated minimal activity as a single agent in both cell

PILLING
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lines tested. Interestingly, LNCaP‐AR cells were more sensitive to

Furthermore, the CI values showed significant synergy in a range

proTAME as single‐agent; however, the drug had only moderate

of doses for both LNCaP‐AR and 22Rv1. Since 5 µM of proTAME

activity in both cell lines. To evaluate the effect of APC/C in-

synergistically reduced cell viability with several low doses of

hibition in cell lines that display mitotic slippage in response to

DTX, we evaluated clonogenic survival of the drug combinations

DTX, CRPC cell lines LNCaP‐AR and 22Rv1 were treated with

in CRPC cells (Figure 5C). Here, both cell lines show a significant

three increasing doses of apcin or proTAME in combination with

reduction in clonogenic survival when treated with 5 µM of

DTX. Evaluation of cell viability showed that only high doses of

proTAME in combination with 1 nM DTX. Although targeting

apcin (50 and 75 µM) increased DTX sensitivity (Figure 5A). To

mitotic exit through inhibition of APC/C has significant clinical

determine if any of the dose combinations synergistically de-

potential, neither apcin nor proTAME have been tested clinically.

creased cell viability, we calculated the combination indexes (CI)

Based on our findings, we hypothesized that therapies that acti-

from the drug dose combinations using the Bliss model of synergy

vated the spindle checkpoint in cells undergoing mitotic stress

where CI values <0.5 indicates synergism, 0.5–1.0 is additive;

would be effective at overcoming resistance to anti‐mitotic

and >1.0 no synergism. 26 As shown in the CI heatmap for

agents such as DTX. Polo‐like kinase 1 (PLK1) regulates several

LNCaP‐AR, most of the doses of apcin tested did not synergize

cell‐cycle processes including k‐MT stabilization and activation of

with DTX. In 22Rv1 cells, the majority of low doses of apcin

APC/C. 27,28 Furthermore, PLK1 is a druggable target with several

showed minimal effect on cell viability in combination with DTX,

inhibitors currently in clinical trials.29 We evaluated volasertib, an

however, several high doses of apcin were effective and appeared

ATP‐competitive inhibitor of PLK1, currently tested in phase III

to be moderately synergistic. Combination with proTAME proved

clinical trials in AML. We first tested volasertib single‐agent

to be more effective in sensitizing the CRPC cells to DTX, de-

efficacy in both CRPC cell lines (Figure S4). Interestingly, both

monstrating a more than threefold increase in DTX sensitivity at

cell lines showed sensitivity at high doses of volasertib with

the lowest dose of proTAME in both cell lines tested (Figure 5B).

LNCaP‐AR cells exhibited more than fivefold greater sensitivity

F I G U R E 5 Blocking mitotic progression sensitizes CRPC cells to docetaxel. (A, B, D) Viability of LNCaP‐AR and 22Rv1 cells treated with
DTX alone or in combination with the indicated doses of apcin (A) or proTAME (B) or volasertib (D) for 72 h. Heatmaps show combination index
(CI) for all dose combinations. Synergy score was calculated using the Bliss independence Model. CI < 0.5 indicates synergism, 0.5–1.0 is
additive; and >1.0 no synergism. (C), Clonogenic survival of CRPC cells treated with DTX, proTAME, or the combination. (E) Clonogenic survival
of CRPC cells treated with DTX, volasertib, or the combination. (F) Western blot analysis for markers of mitotic checkpoint activation and
apoptosis in LNCaP‐AR and 22Rv1 cells treated with DTX alone or in combination with volasertib for 18 h. *p < .01. CRPC, castration‐resistant
prostate cancer; DTX, docetaxel [Color figure can be viewed at wileyonlinelibrary.com]
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compared to 22Rv1 cells. To evaluate the effect of PLK1 inhibi-

observed decreased checkpoint activation and mitotic arrest in

tion in combination with DTX, we tested three doses of volasertib

response to DTX in AR‐reactivated CRPC cells, supporting our

that included IC25 and IC50 of both cell lines. Our results de-

hypothesis that aberrant AR signaling was involved in DTX

monstrated that combination of volasertib and DTX caused

resistance.

stronger inhibition of cell viability than what was conferred by

We mechanistically examined the interaction of AR on mitotic

each drug alone in both CRPC cell lines tested (Figure 5D). Fur-

checkpoint signaling and identified a novel mechanism where AR

thermore, calculation of the CI values showed strong synergy

disrupts SAC signaling in response to DTX by negatively regulating

with DTX at low doses of volasertib (10 nM, 20 nM) in both cell

AURKB activation. AURKB is part of the SAC and functions in de-

lines. We then evaluated clonogenic survival using the lowest

stabilizing microtubules to achieve correct bi‐orientation of chro-

dose of volasertib (10 nM) in combination with DTX and de-

mosomes during mitosis. Since the mechanism of action of DTX is

monstrate that the drug combination significantly decreases

through microtubule binding and subsequent SAC activation, it is

clonogenic

cells

likely that DTX resistance in AR reactivated tumors is driven by mi-

(Figure 5E). To support our hypothesis that blocking mitotic exit

totic checkpoint override, resulting in premature mitotic exit and

would sensitize cells to DTX by forcing AURKB activation and

evasion of apoptosis. To therapeutically target mitotic exit, we tested

mitotic arrest, we evaluated mitotic checkpoint signaling with the

two APC/C inhibitors, apcin and proTAME, and showed that only

drug combination in LNCaP‐AR and 22Rv1 cells. Indeed, addition

proTAME was synergistic with DTX in the CRPC cells. The con-

of volasertib resulted in strong AURKB activation and mitotic

trasting response observed with two APC/C inhibitors likely reflects

arrest; and robustly induced apoptosis compared to DTX alone

the different mechanisms of action of the two drugs, suggesting that

(Figure 5F). Taken together, these results suggest that DTX re-

blocking the interaction between APC/C and CDC20 with proTAME

sistance in CRPC cells is mediated through mechanisms that

is more effective due to increased dependence on CDC20 for APC/C

override spindle checkpoint activation, suggesting that blocking

activation in the CRPC cells. However, since APC/C inhibitors have

mitotic exit is an attractive therapeutic target to overcome DTX

not been tested clinically, we searched for a target whose inhibition

resistance CRPC.

would block mitotic exit and is clinically actionable. PLK1 is a multi-

survival

in

both

LNCaP‐AR

and

22Rv1

functional kinase that has been shown to promote anaphase progression by increasing CDC20 binding and APC/C activation.
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Importantly, it is frequently overexpressed in many cancers including
prostate and was recently shown to induce resistance to T‐DM1, an

Although DTX has been shown to provide a survival benefit in pa-

anti‐mitotic therapy in breast cancer, through mitotic slippage.31

tients with metastatic CRPC, drug resistance remains a major clinical

Combination of volasertib and DTX in the CRPC lines showed strong

challenge. Knowledge of the mechanisms governing DTX resistance

synergism with low, clinically achievable doses of DTX, demonstrat-

in CRPC is critical to develop novel therapeutic strategies to improve

ing the potential to overcome DTX and eliminate dose‐related

outcomes in these patients. Several proposed mechanisms of DTX

toxicities.

resistance include aberrations in drug efflux pump activity, alterations

Increased knowledge of the role of aberrant AR activation on

in microtubule structure and function, activation of cell survival

DTX response has revealed a potential link between DTX mechanism

pathways, or defects in apoptosis signaling.30 However, these me-

of action and AR signaling. Several studies have shown that the

chanisms are ubiquitous among anti‐mitotic drugs and do not address

microtubule‐targeting activity of DTX disrupts AR translocation into

the potential role of biological drivers underlying resistance to

the nucleus, effectively blocking AR signaling and may mediate the

taxane‐based therapies.

majority of DTX's efficacy.32,33 In this context, the increased pre-

The development of CRPC from castration‐sensitive disease

valence of mutated or splice variant of forms of AR found in CRPC

frequently involves acquisition of AR alterations including acti-

may be a critical determinant of DTX response. This was demon-

vating mutations, copy‐number gains, amplification, and expres-

strated in a recent prospective study where detection of AR‐v7 was

sion of ARVs that can maintain adequate AR activity to fuel tumor

associated with inferior PSA decrease in response to taxane treat-

growth. In this study, we investigated the role of AR activation in

ment.34 Another potential outcome from the inhibitory effect of

DTX resistance to identify AR‐dysregulated pathways that can be

taxanes on AR transactivation is that it provides a selective en-

therapeutically targeted to overcome drug resistance. We

vironment to overcome taxane‐induced disruption of microtubule

showed that activating AR in CSPC cells decreased DTX sensi-

dynamics. Indeed, several recent studies have reported enrichment of

tivity through mechanisms involving the G2/M checkpoint. Cell‐

dysregulated G2/M checkpoint and mitotic phase signaling in CRPC,

cycle analysis revealed that AR activation attenuated the G2/M

suggesting that underlying molecular alterations that confer DTX

arrest in response to DTX, suggesting aberrant AR signaling is

resistance are acquired in CRPC.20,35,36 Our findings show that sig-

involved in dysregulating mitotic checkpoint processes. Further

naling controlling microtubule dynamics and mitotic progression is

evaluation of checkpoint signaling showed that AR negatively

dysregulated under AR‐driven conditions and suggest that targeting

regulates AURKB signaling, effectively overriding the checkpoint

this aberrant signaling is a potential therapeutic strategy to overcome

and inducing a phenotype of mitotic slippage. Importantly, we

DTX resistance in CRPC (Figure 6).
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F I G U R E 6 Schematic representation of the proposed model of AR‐dysregulated mitotic checkpoint signaling and docetaxel resistance.
Upper panel shows model of DTX cytotoxicity when AR is inhibited in CSPC. DTX binds microtubules and induces SAC activation, leading to
prolonged mitotic arrest and apoptosis. Lower panel depicts DTX resistance when AR is activated or aberrantly reactivated, as is frequently
observed in CRPC. Activated AR inhibits SAC activation, resulting in failed mitotic arrest, followed by premature mitotic progression (mitotic
slippage) and DTX resistance. Targeting anaphase activators such as CDC20, APC/C or PLK1 is a potential therapeutic strategy to overcome
DTX resistance in CRPC. APC/C, anaphase‐promoting complex/cyclosome; AR, androgen receptor; CRPC, castration‐resistant prostate cancer;
CSPC, castration‐sensitive prostate cancer; DTX, docetaxel; PLK1, polo‐like kinase 1 [Color figure can be viewed at wileyonlinelibrary.com]
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